ImmunoCellular Therapeutics (FRA:KOL1) Forward PE Ratio : 0.00 (As of Jun. 17, 2024)

ImmunoCellular Therapeutics Forward PE Ratio Chart

Competitive Comparison of ImmunoCellular Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, ImmunoCellular Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoCellular Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoCellular Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ImmunoCellular Therapeutics's Forward PE Ratio falls into.

ImmunoCellular Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

ImmunoCellular Therapeutics  (FRA:KOL1) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

ImmunoCellular Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of ImmunoCellular Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoCellular Therapeutics (FRA:KOL1) Business Description